About
Cancer Therapies
Areas of Focus
Categories
Biologics & BiopharmaceuticalAntibody
Clinical Trials (7)
View allTotal Trials
7
As Lead Sponsor
5
As Collaborator
2
Total Enrollment
864
By Phase
PHASE2: 3PHASE1/PHASE2: 2PHASE3: 1PHASE1: 1
By Status
ACTIVE_NOT_RECRUITING: 3UNKNOWN: 2RECRUITING: 1TERMINATED: 1
Clinical Trials Pipeline7 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Today
Hover over trial bars to see details
Recent Trials
NCT05605535Lead Sponsor
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer
PHASE2Active, not recruiting
88 participants
Started: Feb 7, 2023 · Completed: Sep 15, 2027
NCT05335993Lead Sponsor
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
PHASE2Active, not recruiting
10 participants
Started: Jul 25, 2022 · Completed: Jul 30, 2025
NCT05407584Collaborator
Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
PHASE2Unknown
56 participants
Started: Jul 5, 2022 · Completed: Nov 30, 2024
NCT04938583Lead Sponsor
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
PHASE1/PHASE2Recruiting
54 participants
Started: Mar 17, 2021 · Completed: Dec 31, 2025
NCT04620954Collaborator
Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin
PHASE1/PHASE2Unknown
31 participants
Started: Oct 7, 2020 · Completed: Jul 31, 2022
Locations (1)
Headquarters
Seoul, Korea
Map
Loading map...